Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw

• 作者: Lina He Xiangyu Sun Yanfen Qiu Yumei Niu Zhijie Liu
• 来源期刊: 国际口腔科学杂志（英文版）
• 年，卷（期）: 2020,（3）
• 所属期刊栏目: REVIEWS
• 页码范围: 209-219
• 页数: 11页
• 语种: 英文

摘要

INTRODUCTION Bisphosphonates (BPs) are the most widely used antiresorptive drugs in the management of cancer-related conditions, such as the prevention of bone metastatic malignancies, and are also used for the treatment and prevention of osteoporosis. However, since the reporting of the first case of osteonecrosis of the jaw (ONJ) in cancer patients who had been treated with high-dose BPs in 2003,1 it has been acknowledged that bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a serious adverse reaction to BPs. In response to the incidence of adverse reactions to another bone-modifying agent (BMA), denosumab, or the angiogenesis inhibitor agent bevacizumab, the American Association of Oral and Maxillofacial Surgeons (AAOMS) renamed BRONJ'medication-related osteonecrosis of the jaw' (MRONJ),2 as described in a key paper (2014) from the AAOMS.